ASD CB-MNC injection.
Biologic
ASD CB-MNC injection. is one of 13 biologic programs targeting Blood Transfusion. It is currently in development.
1
Indications
2
Total Trials
0
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
33 competitors in Blood Transfusion
#DrugCompanyPhaseTrials
1Cyklokapron
AAmring
Approved
Desferal
Alnylam PharmaceuticalsPhase 3
Ferinject
VVifor Pharma
Approved
Exjade
NovartisPhase 2
ICL670
NovartisPhase 3
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Iron Sulphate
PPierre Fabre Pharma GmbH
Phase 1
Umbilical Cord Blood Unit
WWeill Medical College of Cornell University
Phase 2
N-Acetylcystine
UUniversity of California, San Francisco
Phase 1
Red Blood Cell
UUniversity of Pittsburgh
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Blood Transfusion1 trial
Allogenic Cord Blood Transfusion in Patients With Autism
Completed·SState-Financed Health Facility "Samara Regional Medical Center Dinasty"·Phase 1/2·NCT03786744·20 enrolled
Safety and Efficacy1 trial
Safety and Efficacy of the Transfusion of UCB in Patients With an ASD Depending on the Degree of HLA Compatibility.
Unknown status·SState-Financed Health Facility "Samara Regional Medical Center Dinasty"·Phase 1/2·NCT04099381·150 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ASD CB-MNC injection.. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]